FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| Check this box if no longer subject to<br>Section 16. Form 4 or Form 5 | STATEMENT OF CHANGES IN BENEFICIAL OWNE | RSHIP |
|--|---|-------|
|--|---|-------|

**OMB APPROVAL** OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Underdown Brian J.</u>          |  |  |  |                 | 2. Issuer Name and Ticker or Trading Symbol VistaGen Therapeutics, Inc. [ VTGN ] |   |                              |  |                    |   |  | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |  |  |  |  |
|---|--|--|--|-----------------|--|---|------------------------------|--|--------------------|---|--|---|--|--|--|--|
|   |  |  |  | -               |  |   |                              |  |                    |   | :  | X Directo   | or   | 10% Ov   | vner   |  |
| (Last) (First) (Middle) C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE |  |  |  |                 | 3. Date of Earliest Transaction (Month/Day/Year) 06/19/2016                      |   |                              |  |                    |   |  | Officer<br>below)   | (give title  | Other (s<br>below)   | specify  |  |
| (Street) SOUTH SAN FRANCISCO CA 94080                                       |  | 4.                                     | 4. If Amendment, Date of Original Filed (Month/Day/Year) |                 |  |   |                              |  | Line               | ndividual or Joint/Group Filing (Check Applicable e)  X Form filed by One Reporting Person Form filed by More than One Reporting Person |  |   |  |  |  |  |
| (City)  | (S   | tate)                                  | (Zip)  |                 |  |   |                              |  |                    |   |  |   |  |  |  |  |
|   | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned   |  |  |                 |  |   |                              |  |                    |   |  |   |  |  |  |  |
| Date  |  |  | ransaction<br>e<br>enth/Day/Y                            | Execution Date, |  | Code (Inst  | on Disposed<br>tr. 5)        | ties Acquired (A) o<br>d Of (D) (Instr. 3, 4 a<br>(A) or<br>(D) Pric |                    | Beneficia   | es Fo<br>ally (D<br>following (I)<br>I<br>ion(s) | orm: Direct<br>) or Indirect<br>(Instr. 4)                              | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>Instr. 4)   |  |  |  |
|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |  |  |                 |  |   |                              |  |                    |   |  |   |  |  |  |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                         | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | Date Execution (Month/Day/Year) if any | 3A. Deemed<br>Execution Date<br>if any<br>(Month/Day/Yea | Code            |  | 5. Numb<br>of<br>Derivati<br>Securiti<br>Acquire<br>(A) or<br>Dispose<br>of (D) (II<br>3, 4 and | ve<br>es<br>d<br>ed<br>nstr. | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year)       |                    | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4)   |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)                     | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |  |
|   |  |  |  | Code            | v  | (A)   | (D)                          | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares           |   |  |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)  | \$3.49   | 06/19/2016                             |  | A               |  | 25,000  |                              | (1)  | 06/19/2026         | Common<br>Stock   | 25,000   | \$0   | 25,000   | D  |  |  |

## **Explanation of Responses:**

1. 25% of the shares subject to the option shall vest on the one year anniversary of the Grant Date and 1/48th of the shares subject to the option shall vest monthly every month thereafter until all awarded shares are fully vested.

/s/ Jerrold D. Dotson, Attorney-06/21/2016 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.